---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-004719"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2023-07-07T23:59:59+00:00"
generated_at: "2026-06-13T11:03:47.786687+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health extends notes from directors/officers and LGH to late 2023; conversion price set at $0.12

## Summary
- Extended maturity on five promissory notes from directors/officers to Oct 31, 2023; conversion price $0.12/share.
- Extended $1,050,000 LGH convertible note maturity to Dec 31, 2023; $25,000 added to principal.
- LGH note interest set at 8% per annum; conversion price fixed at $0.12 per share.
- All other terms and conditions of the notes remain unchanged.

## SEC filing metadata
- accession: 0001683168-23-004719
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2023-07-07T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316823004719/0001683168-23-004719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316823004719/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-004719
- JSON: https://secwatch.observer/filing/0001683168-23-004719.json
- Plain text: https://secwatch.observer/filing/0001683168-23-004719.txt

## Key facts
- Debt Financings
  Odyssey Health, Inc. amended convertible notes with three directors and two officers of the Company maturing October 31, 2023.
  - Instrument: convertible notes
  - Counterparty: three directors and two officers of the Company
  - Maturity: October 31, 2023
  - Event: amendment
  source text: On June 30, 2023, Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (the “Company”), entered into five Promissory Note Amendments (the “Amendments”), to the Promissory Notes entered into December 21, 2021 and December 22, 2021 and as amended April 20, 2022, June 3, 2022 and September 30, 2022, December 30, 2023 and March 31, 2023 with three directors and two officers of the Company. Pursuant to the Amendments, the parties have agreed to extend the maturity date of the note to October 31, 2023 and the lender may convert the note prior to maturity at a conversion price of $0.12 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626644/000168316823004719/0001683168-23-004719-index.htm
- Debt Financings
  Odyssey Health, Inc. amended convertible notes of $25,000 with LGH Investments, LLC at eight percent (8%) per annum maturing December 31, 2023.
  - Instrument: convertible notes
  - Principal: $25,000
  - Counterparty: LGH Investments, LLC
  - Rate: eight percent (8%) per annum
  - Maturity: December 31, 2023
  - Event: amendment
  source text: On July 6, 2023, the Company entered into Amendment No. 6 to the Convertible Promissory Note (the “Amendment”) to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC (“LGH”). Pursuant to the Amendment, the parties have agreed to extend the maturity date of the note to December 31, 2023. As consideration, twenty five thousand ($25,000) shall be added to the principal amount outstanding, the interest rate of eight percent (8%) per annum shall be charged on the unpaid principal amount from the effective date and the conversion price shall be twelve cents ($0.12) per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626644/000168316823004719/0001683168-23-004719-index.htm
- Material Agreements
  Odyssey Health, Inc. amended Amendment No. 6 to the Convertible Promissory Note with LGH Investments, LLC valued at Extended maturity date to December 31, 2023; added $25,000 to principal; 8% interest; conversion pri (effective 2023-07-06).
  - Action: amendment
  - Agreement: notes offering
  - Counterparty: LGH Investments, LLC
  - Value: Extended maturity date to December 31, 2023; added $25,000 to principal; 8% interest; conversion pri
  - Effective: 2023-07-06
  source text: On July 6, 2023, the Company entered into Amendment No. 6 to the Convertible Promissory Note (the “Amendment”) to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC (“LGH”). Pursuant to the Amendment, the parties have agreed to extend the maturity date of the note to December 31, 2023. As consideration, twenty five thousand ($25,000) shall be added to the principal amount outstanding, the interest rate of eight percent (8%) per annum shall be charged on the unpaid principal amount from the effective date and the conversion price shall be twelve cents ($0.12) per share. All other terms and conditions remain the same.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626644/000168316823004719/0001683168-23-004719-index.htm
- Material Agreements
  Odyssey Health, Inc. amended Promissory Note Amendments with three directors and two officers valued at Extended maturity date to October 31, 2023; conversion price $0.12 per share (effective 2023-06-30).
  - Action: amendment
  - Agreement: notes offering
  - Counterparty: three directors and two officers
  - Value: Extended maturity date to October 31, 2023; conversion price $0.12 per share
  - Effective: 2023-06-30
  source text: On June 30, 2023, Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (the “Company”), entered into five Promissory Note Amendments (the “Amendments”), to the Promissory Notes entered into December 21, 2021 and December 22, 2021 and as amended April 20, 2022, June 3, 2022 and September 30, 2022, December 30, 2023 and March 31, 2023 with three directors and two officers of the Company. Pursuant to the Amendments, the parties have agreed to extend the maturity date of the note to October 31, 2023 and the lender may convert the note prior to maturity at a conversion price of $0.12 per share. All other terms and conditions remain the same.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626644/000168316823004719/0001683168-23-004719-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.
